🇪🇺 YKP3089 in European Union

EMA authorised YKP3089 on 26 March 2021

Marketing authorisation

EMA — authorised 26 March 2021

  • Application: EMEA/H/C/005377
  • Marketing authorisation holder: Angelini Pharma S.p.A
  • Local brand name: Ontozry
  • Indication: Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
  • Status: approved

Read official source →

YKP3089 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is YKP3089 approved in European Union?

Yes. EMA authorised it on 26 March 2021.

Who is the marketing authorisation holder for YKP3089 in European Union?

Angelini Pharma S.p.A holds the EU marketing authorisation.